Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2014 Sep 25;34(12):2586–2593. doi: 10.1161/ATVBAHA.114.304530

Figure 2.

Figure 2

Binding specificity and effects of an a2AP inactivating (a2AP-I) monoclonal antibody and TPA on thrombus dissolution, infarction, swelling and hemorrhage after thromboembolism. A) The a2AP-I monoclonal antibody binds specifically to mouse a2AP vs. BSA in an ELISA by comparison to a control (anti-digoxin) monoclonal antibody. See Methods for additional details. B) The a2AP-I (o) accelerates the dissolution of 125I-fibrin labeled mouse plasma clots in vitro by comparison to no monoclonal antibody (●). Clot dissolution was determined as described in Methods. Effect of a2AP-I (9 mg/kg) or TPA (10 mg/kg) treatment given 2.5 hour after thromboembolism on the percent C) brain infarction, D) thrombus dissolution, E) brain swelling and F) hemorrhage. Brains were examined 6 h after cerebral thromboembolism. Data represent the means ± SE. n = 7 mice per group (B-E). *p≤0.05, ***p≤0.001, NS not significant.